Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-08049820 MR1 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Treatment A | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 short Modified release (MR) release rate (MR1) tablets under fasted conditions. |
| Treatment B | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 long MR release rate (MR2) tablets under fasted conditions. |
| Treatment C | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 Immediate Release (IR) tablets under fasted conditions. |
| Treatment D | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 MR2 tablets under fed conditions. |
| Treatment E | EXPERIMENTAL | Participants will receive a single dose of PF-08049820 IR tablets under fed conditions. |
| Name | Type | Description |
|---|---|---|
| PF-08049820 MR1 | DRUG | Administered orally |
| PF-08049820 MR2 | DRUG | Administered orally |
| PF-08049820 IR | DRUG | Administered orally |
Inclusion Criteria: * Male and female participants of non-childbearing potential ≥18 years of age * BMI of 16-32 kg/m2; and a total body weight \>45 kg (99 lbs) * Participants who are willing and able to comply with all scheduled visits, treatment plan, laboratory tests, and other study procedures....
Top 20 of 25 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 9 | PHASE3 | Upadacitinib, corticosteroids |
| Pfizer Inc. | PFE | 11 | PHASE3 | Abrocitinib |
| Eli Lilly and Company | LLY | 4 | PHASE3 | Lebrikizumab, Corticosteroid |
| Sanofi SA Sponsored ADR | SNY | 13 | PHASE3 | Amlitelimab |
| Regeneron Pharmaceuticals, Inc. | REGN | 4 | PHASE3 | Dupilumab |
| Incyte Corporation | INCY | 3 | PHASE3 | Ruxolitinib, Vehicle |
| Organon & Co. | OGN | 1 | PHASE3 | Tapinarof, 1%, Vehicle |
| Apogee Therapeutics, Inc. | APGE | 3 | PHASE2 | APG777 |
| Novartis AG Sponsored ADR | NVS | 2 | PHASE2 | GIA632 |
| Johnson & Johnson | JNJ | 1 | PHASE2 | JNJ-95597528 |
| Kymera Therapeutics, Inc. | KYMR | 1 | PHASE2 | KT-621 |
| Corvus Pharmaceuticals, Inc. | CRVS | 1 | PHASE2 | Soquelitinib |
| Nektar Therapeutics | NKTR | 1 | PHASE2 | Rezpegaldesleukin |
| Celldex Therapeutics, Inc. | CLDX | 1 | PHASE2 | Barzolvolimab |
| Evommune, Inc. | EVMN | 1 | PHASE2 | EVO756 |
| Sunshine Biopharma Incorporated | SBFM | 3 | PHASE3 | 611, corticosteroid |
| Aclaris Therapeutics, Inc. | ACRS | 1 | PHASE2 | ATI-045 |
| Q32 Bio Inc | QTTB | 1 | PHASE2 | ADX-914 |
| Turn Therapeutics Inc. | TTRX | 1 | PHASE2 | GX-03 |
| Arcutis Biotherapeutics Inc | ARQT | 1 | PHASE1 | ARQ-234 |
PF-08049820 MR1 is an investigational small molecule being studied for the treatment of atopic dermatitis, a chronic inflammatory skin condition. It is currently in Phase 1 clinical development and has not been approved by regulatory authorities.
PF-08049820 MR1 is being developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is in early-stage clinical development for atopic dermatitis.
PF-08049820 MR1 is in Phase 1 clinical development. It is an investigational drug and has not been approved for any use. One Phase 1 study has been completed, and the drug remains under evaluation for atopic dermatitis.
PF-08049820 MR1 has one completed Phase 1 trial, NCT07172321, which studied how different forms of the drug are absorbed into the bloodstream in healthy adults. The trial enrolled 12 participants in the United States and was a controlled, randomized study.
PF-08049820 MR1 is not FDA approved. It is an investigational drug in Phase 1 clinical development for atopic dermatitis. The completed trial, NCT07172321, was a pharmacokinetic study in healthy volunteers, and the drug has not yet progressed to later-stage trials.